Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
ciprofloxacin, Quantity: 200 mg
Pfizer Australia Pty Ltd
Ciprofloxacin
Injection, solution
Excipient Ingredients: hydrochloric acid; lactic acid; water for injections; glucose monohydrate
Intravenous
50 pack
(S4) Prescription Only Medicine
Ciprofloxacin Injection for Intravenous Infusion is indicated for use in the following: 1. Hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. 2. For the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems: - Lower respiratory tract infections (gram-negative organisms). Skin and skin structure. Septicaemia. Bone and joint. Urinary tract. 3. Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans serve as surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. Note: Because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram positive infections due to Streptococcus pneumoniae. If anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. Strains of Neisseria gonorrhoea resistant to ciprofloxacin have been reported in Australia. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. Ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram positive aerobic bacteria. If anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.
Visual Identification: Clear, colourless or slightly yellow solution; Container Type: Bag; Container Material: Plastic; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2006-12-15
DBL™ CIPROFLOXACIN INJECTION FOR INTRAVENOUS INFUSION _Ciprofloxacin_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about DBL Ciprofloxacin Injection for Intravenous Infusion. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you being given DBL Ciprofloxacin Injection for Intravenous Infusion against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT BEING GIVEN THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. You may need to read it again. WHAT DBL CIPROFLOXACIN INJECTION FOR INTRAVENOUS INFUSION IS USED FOR This medicine is used to treat: • lung infections • infections of skin • infections of bone and joints • kidney and bladder infections • infections in the blood • inhalation of anthrax (post- exposure). This medicine belongs to a group of medicines called fluoroquinolones. It works by killing many kinds of bacteria which cause infections in the body. DBL Ciprofloxacin Injection for Intravenous Infusion will not work against infections caused by viruses such as cold and flu. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. This medicine is not addictive. It is available only with a doctor's prescription. BEFORE YOU ARE GIVEN DBL CIPROFLOXACIN INJECTION FOR INTRAVENOUS INFUSION _WHEN YOU MUST NOT BE GIVEN_ _IT_ YOU MUST NOT BE GIVEN DBL CIPROFLOXACIN INJECTION FOR INTRAVENOUS INFUSION IF YOU HAVE AN ALLERGY TO: • any medicine containing ciprofloxacin • any of the ingredients listed at the end of this leaflet • any other quinolone antibiotics such as moxifloxacin, nalidixic acid or norfloxacin. Some of the symptoms of an allergic reaction may include: • shortness of breath • wheezing or difficulty breathing • swelling of the face, lips, tongue or othe Read the complete document
Version: pfpcipdi11121 Supersedes: pfpcipdi11020 Page 1 of 24 AUSTRALIAN PRODUCT INFORMATION – DBL™ CIPROFLOXACIN INJECTION FOR INTRAVENOUS INFUSION BAG (CIPROFLOXACIN) 1. NAME OF THE MEDICINE Ciprofloxacin 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DBL Ciprofloxacin Injection for Intravenous Infusion is a synthetic carboxyquinolone derivative with broad spectrum antimicrobial activity for intravenous (IV) administration. Ciprofloxacin, a fluoroquinolone, is a 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1- piperazinyl)-3-quinoline-carboxylic acid. Ciprofloxacin is a white to pale yellow crystalline powder. DBL Ciprofloxacin Injection for Intravenous Infusion is available as a ciprofloxacin (as lactate) 100 mg/50 mL, 200 mg/100 mL and 400 mg/200 mL infusion solution. It also contains the excipients lactic acid (as a solubilising agent), glucose monohydrate 50 mg/mL and water for injections. Hydrochloric acid is added as necessary to adjust the pH. EXCIPIENT(S) WITH KNOWN EFFECT • Glucose monohydrate For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM DBL Ciprofloxacin Injection for Intravenous Infusion is a clear, colourless, or slightly yellow solution, available in infusion bags. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS DBL Ciprofloxacin Injection for Intravenous Infusion is indicated for use in the following: 1. Hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. 2. For the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems: - Lower respiratory tract infections (gram-negative organisms) - Skin and skin structure - Septicaemia Version: pfpcipdi11121 Supersedes: pfpcipdi11020 Page 2 of 24 - Bone and joint - Urinary tract 3. Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized _Bacillus anthracis._ Ciprofloxacin serum concentrations achieved Read the complete document